A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study of GIC-1001 for the Management of Visceral Pain in Subjects Undergoing Sedation-Free, Full Colonoscopy

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study of GIC-1001 for the Management of Visceral Pain in Subjects Undergoing Sedation-Free, Full Colonoscopy

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Aug 2016

At a glance

  • Drugs Trimebutine 3-thiocarbamoylbenzenesulfonate (Primary)
  • Indications Procedural pain
  • Focus Therapeutic Use
  • Sponsors gIcare Pharma
  • Most Recent Events

    • 19 Mar 2014 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
    • 18 Feb 2014 According to ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.
    • 26 Aug 2013 New source identified and integrated (Mayo Clinic; 13-004262).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top